PSMA-PET/CT helps spot early prostate cancer recurrence
PET/CT imaging with gallium-68 prostate-specific membrane antigen (PSMA-11)...Read more on AuntMinnie.comRelated Reading: SNMMI: PET/CT with prostate agent changes therapy plans SNMMI: PET/CT may help guide prostate biopsies New PET tracer aids in metastatic prostate cancer PET tracer boosts detection of recurrent prostate cancer SNMMI: PET beats other modalities for prostate cancer
Blue Earth Diagnostics said that its Axumin (fluciclovine F-18) PET radiopharmaceutical...Read more on AuntMinnie.comRelated Reading: Blue Earth highlights Axumin clinical results at ASTRO Blue Earth touts Axumin reader training results Novel PET tracer aids recurrent prostate cancer patients Medicare coverage gets easier for oncologic PET tracers Blue Earth PET radiotracer IDs prostate cancer recurrence
Among a prospectively followed cohort of 471 men treated with radiation therapy for prostate cancer, we demonstrate that sexual aid use is common at baseline, increases with time, and is helpful to many. However, a substantial number of men reported benefit, but were not currently using aids, and future study is required to optimize post-treatment sexual function.
Conclusions: Participants believed the decision aid helped them become more aware of their personal values, assisted in their treatment decision making, and facilitated an interactive patient–healthcare provider relationship. Implications for Practice: Decision aids assist patients, decision partners, and healthcare providers make satisfying treatment decisions that affect quality/quantity of life. These findings are important for understanding the experiences of patients who have to make difficult decisions.
BY SHANNON BROWNLEE On Wednesday, October 25, 2017 I was at the inaugural Society for Participatory Medicine conference. It was a fantastic day and the ending keynote was the superb Shannon Brownlee. It was great to catch up with her and I’m grateful that she agreed to let THCB publish her speech. Settle back with a cup of coffee (or as it’s Thanksgiving, perhaps something stronger), and enjoy–Matthew Holt George Burns once said, the secret to a good sermon is to have a good beginning and a good ending—and to have the two as close together as possible. I think the same is true of final keynotes aft...
Publication date: November 2017 Source:Spatial and Spatio-temporal Epidemiology, Volume 23 Author(s): Susanna M. Cramb, Paula Moraga, Kerrie L. Mengersen, Peter D. Baade Interpreting changes over time in small-area variation in cancer survival, in light of changes in cancer incidence, aids understanding progress in cancer control, yet few space–time analyses have considered both measures. Bayesian space–time hierarchical models were applied to Queensland Cancer Registry data to examine geographical changes in cancer incidence and relative survival over time for the five most common cancers (colorectal, melanom...
Your browser does not support iframes. Although not as well-known as other medical conditions, sepsis kills more people in the United States than AIDS, breast cancer, or prostate cancer combined. Sepsis is body-wide inflammation, usually triggered by an overwhelming immune response to infection. Though doctors and medical staff are well-aware of the condition—it is involved in 1 in 10 hospital deaths—the condition is notoriously hard to diagnose. In this video, sepsis expert Sarah Dunsmore, a program director with the National Institute of General Medical Sciences (NIGMS), describes what sepsis is and how to re...
A broader range of decisional tools should be investigated. This paper will update the decisional outcome data and assess the features of decisional tool. Literature search strictly followed the PRISMA guideline. Articles that cited Lin et al. and Violette et al. were searched. Features of decisional tools were analyzed using the IPDASi criteria. The scores of the 31 decisional tools ranged from 6 to 15, which did not correlate proportionally with the positive decisional outcomes. Personal importance appeared to be a significant co mponent.
A broader range of decisional tools should be investigated. This paper will update the decisional outcome data and assess the features of decisional tool. Literature search strictly followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline. Articles that cited Lin et al and Violette et al were searched. Features of decisional tools were analyzed using the International Patient Decision Aid Standards Instrument criteria. The scores of the 31 decisional tools ranged from 6 to 15, which did not correlate proportionally with the positive decisional outcomes.
This article intends to give an educational overview on the current status of PSMA ligand PET imaging, including imaging procedure and interpretation, clinical indications, diagnostic potential, and impact on treatment planning.
Cross specialty primary care of patients with prostate cancer is challenging as patients face difficult treatment decisions due to multiple equivalent treatment options, an individual mix of comorbidities, personal preferences and considerable psychological burden following a cancer diagnosis. Several decision aids exist, but these have primarily been targeted to physicians and their effects have not been studied by means of evidence based medicine. To mitigate, patients increasingly turn to internet-based research before and after consultations.